Daipon Pharmaceutical Industries Co., Ltd.
Basic information
- Head office
- 1-27 Kanda Nishikicho, Chiyoda-ku, Tokyo 101-8444
- Chief executive
- Shou-ichi Kobayashi
- Capital
- 200,000,000 JPY (2 100 millionJPY)
- Employees (non-consolidated)
- 2,149 people
- Employees (consolidated)
- 2,149 people
- Start date
- 1963-06-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Ariruju Co., Ltd. | ||||||||
| Okayama Daipō Pharmaceutical Co., Ltd. |
Network
History
A contract was signed with the Soviet Union Pharmaceutical Import-Export Agency for the introduction of "Futuraul."![]()
A business alliance and capital participation were established with Antibody Chemical Industry. A GMP-compliant injection drug plant was completed in the Tokushima Factory, and plant consolidation was finished.![]()
The headquarters factory of Antibody Chemical Industry Co., Ltd. (100% owned) was completed in Saitama Prefecture, and the Kodama Research Institute was opened.![]()
Completion of the Drug Discovery Center, Training Center, and Computing Center in Saitama Prefecture![]()
Renamed Shinzen Pharmaceutical to Okayama Daipō Pharmaceutical Co., Ltd. and Antibody Production Industry to Daipō Fine Chemical Co., Ltd.![]()
Signed a license agreement with American BioScience, Inc. (at the time of the contract) for the anticancer drug "Abracasan"![]()
Entered into an asset transfer agreement concerning assets related to fermentation drug development with Astellas Pharma Inc.![]()
Entered into a co‑promotion agreement in Japan for the human anti‑interleukin‑23 (IL‑23) monoclonal antibody product "Tremfeya" with Janssen Pharma Co., Ltd.![]()
Entered into a license agreement with Cullinan Pearl Corp., operated by Cullinan Oncology, Inc. (at the time of the agreement) in the United States.![]()
Entered into a strategic partnership agreement in the oncology field with Taiho Pharmaceutical, Astex Pharmaceuticals, Inc., and Merck & Co., Inc., Kenilworth, N.J., U.S.A.![]()
News
There is no news.
Public records
National Tax Agency basic information1010001021927
- Trade name
- 大鵬薬品工業株式会社
- Trade name (kana)
- タイホウヤクヒンコウギョウ
- Name in English
- Corporation type
- 301
- Address
- 〒101-0054 東京都千代田区神田錦町1丁目27番地
- Postal code
- 1010054
- Prefecture code
- 13
- City code
- 101
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2018-05-09
- Change date
- 2015-10-05
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 01
- Correction type
- 1
- Trade name image ID
- 00049186
- Address image ID
- Sequence number
- 1270957
METI gBizINFO1010001021927
- Corporate number
- 1010001021927
- Trade name
- 大鵬薬品工業株式会社
- Trade name (kana)
- タイホウヤクヒンコウギョウ
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 東京都千代田区神田錦町1丁目27番地
- Postal code
- 1010054
- Prefecture
- 東京都
- Prefecture code
- 13
- City or district
- 千代田区
- City code
- 101
- Street address
- 神田錦町1丁目27番地
- Organisation type
- 301
- Processing type
- 01
- Correction type
- 1
- Status
- Representative
- Capital
- Employees
- 2399
- Employees (male)
- 1755
- Employees (female)
- 630
- Business summary
- 医薬品、医薬部外品、医療機器などの製造及び販売輸出入
- Website URL
- https://www.taiho.co.jp/csr/diverse/
- Year founded
- Business category
- E:製造業
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2018-05-09
- Key information
- 1010001021927